These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38707960)

  • 1. Predictors of Inadequate Serum Urate Response to Low-Dose Febuxostat in Male Patients with Gout.
    Sun W; Zhao X; Dalbeth N; Terkeltaub R; Cui L; Liu Z; Han L; Wang C; Zhang H; Bao Y; Li C; Lu J
    J Inflamm Res; 2024; 17():2657-2668. PubMed ID: 38707960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
    Lertnawapan R; Jatuworapruk K
    Clin Rheumatol; 2021 Jan; 40(1):255-262. PubMed ID: 32607660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
    Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
    Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
    Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K
    Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-centre experience of febuxostat as a second-line urate-lowering therapy.
    Ong SG; Ding HJ
    Malays Fam Physician; 2021 Mar; 16(1):50-55. PubMed ID: 33948142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
    Quilisadio JEC; Salido EO; Penserga EG
    Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allopurinol for chronic gout.
    Seth R; Kydd AS; Buchbinder R; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006077. PubMed ID: 25314636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat.
    Sheer R; Null KD; Szymanski KA; Sudharshan L; Banovic J; Pasquale MK
    Clinicoecon Outcomes Res; 2017; 9():629-639. PubMed ID: 29066924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
    Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
    Sun Y; Li L; Zhou TY; Lu W
    Yao Xue Xue Bao; 2014 Dec; 49(12):1674-83. PubMed ID: 25920196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
    Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
    PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
    Mackenzie IS; Ford I; Nuki G; Hallas J; Hawkey CJ; Webster J; Ralston SH; Walters M; Robertson M; De Caterina R; Findlay E; Perez-Ruiz F; McMurray JJV; MacDonald TM;
    Lancet; 2020 Nov; 396(10264):1745-1757. PubMed ID: 33181081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
    Borghi C; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):983-92. PubMed ID: 27010159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.
    Dalbeth N; Jones G; Terkeltaub R; Khanna D; Fung M; Baumgartner S; Perez-Ruiz F
    Arthritis Res Ther; 2019 Jan; 21(1):8. PubMed ID: 30616614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of febuxostat in chronic gout.
    Beard SM; von Scheele BG; Nuki G; Pearson IV
    Eur J Health Econ; 2014 Jun; 15(5):453-63. PubMed ID: 23719971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.